Sarah B. Noonberg

Insider Reports History

Entity
Individual
Location
331 Oyster Point Boulevard, South San Francisco, CA
Signature
/s/ Debra A. Mohollen, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Sarah B. Noonberg:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Metagenomi, Inc. Chief Medical Officer Common Stock 100K $289K $2.88 Apr 1, 2024 Direct
MARINUS PHARMACEUTICALS, INC. Director Common Stock 14.1K $60.3K $4.28 Jun 18, 2024 Direct
Metagenomi, Inc. Chief Medical Officer Stock Option (Right to Buy) 243K Apr 1, 2024 Direct
Protagonist Therapeutics, Inc Director Stock Option (right to buy) 30K Jan 16, 2023 Direct
MARINUS PHARMACEUTICALS, INC. Director Stock Option (Right to Buy) 10.5K Jun 18, 2024 Direct
Neurogene Inc. Director Stock Option (Right to Buy) 7.7K Jun 14, 2024 Direct

Insider Reports Filed by Sarah B. Noonberg

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MRNS MARINUS PHARMACEUTICALS, INC. Jun 18, 2024 2 $0 4 Jun 20, 2024 Director
NGNE Neurogene Inc. Jun 14, 2024 1 $0 4 Jun 17, 2024 Director
MGX Metagenomi, Inc. Apr 1, 2024 2 $0 4 Apr 3, 2024 Chief Medical Officer
MGX Metagenomi Technologies, LLC Feb 8, 2024 0 $0 3 Feb 8, 2024 Chief Medical Officer
MRNS MARINUS PHARMACEUTICALS, INC. Jan 18, 2024 2 $0 4 Jan 19, 2024 Director
NGNE Neurogene Inc. Jan 16, 2024 1 $0 4 Jan 18, 2024 Director
NLTX Neoleukin Therapeutics, Inc. Jun 8, 2023 1 $0 4 Jun 9, 2023 Director
MRNS MARINUS PHARMACEUTICALS, INC. May 16, 2023 2 $0 4 May 17, 2023 Director
MRNS MARINUS PHARMACEUTICALS, INC. May 16, 2023 0 $0 3 May 17, 2023 Director
PTGX Protagonist Therapeutics, Inc Jan 16, 2023 1 $0 4 Jan 18, 2023 Director
PTGX Protagonist Therapeutics, Inc May 26, 2022 1 $0 4 May 27, 2022 Director
NLTX Neoleukin Therapeutics, Inc. May 12, 2022 1 $0 4 May 16, 2022 Director
PTGX Protagonist Therapeutics, Inc May 27, 2021 1 $0 4 May 28, 2021 Director
NLTX Neoleukin Therapeutics, Inc. May 11, 2021 1 $0 4 May 13, 2021 Director